Federal Register / Vol. 63, No. 96 /Tuesday, May 19, 1998 / Notices 27591

The firm plans to manufacture small

quantities of the listed controlled

substances for incorporation in drug of

abuse detection kits.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 20,

1998.

Dated: May 7, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13334 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on February 17, 1998, Sigma

Chemical Company, Subsidiary of

Sigma-Aldrich Company, 3500 Dekalb

Street, St. Louis, Missouri 63118, made

application by renewal to the Drug

Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Cathinone (1235) .......................... I

Methcathinone (1237) ................... I

Methaqualone (2565) ................... I

Ibogaine (7260) ............................ I

Lysergic acid diethylamide (7315) I

Tetrahydrocannabinols (7370) ...... I

Drug Schedule

4-Bromo-2, 5-dimethoxyamphetamine (7391).I

3,4-Methylenedioxyamphetamine

(7400).

I

3,4-Methylenedioxy-N-ethylamphetamine (7404).I

3,4-Methylenedioxymethamphetamine (7405).I

4-Methoxyamphetamine (7411) .... I

Psilocyn (7438) ............................. I

Normorphine (9313) ..................... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Methylphenidate (1724) ................ II

Amobarbital (2125) ....................... II

Pentobarbital (2270) ..................... II

Secobarbital (2315) ...................... II

Phencyclidine (7471) .................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Ethylmorphine (9190) ................... II

Hydrocodone (9193) ..................... II

Levorphanol (9220) ...................... II

Meperidine (9230) ........................ II

Methadone (9250) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Opium powdered (9639) ............... II

Oxymorphone (9652) .................... II

Fentanyl (9801) ............................ II

The firm plans to repackage and offer

as pure standards controlled substances

in small milligram quantities for drug

testing and analysis.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47. Any such comments,

objections, or requests for a hearing may

be addressed to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than (June 18, 1998).

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic classes of

any controlled substances in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistance

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: May 4, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control Drug Enforcement

Administration.

[FR Doc. 98–13332 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on February 20, 1998, Stepan

Company, Natural Products Department,

100 W. Hunter Avenue, Maywood, New

Jersey 07607, made application to the

Drug Enforcement Administration to be

registered as an importer of coca leaves

(9040) a basic class of controlled

substance in Schedule II.

The firm plans to import coca leaves

to manufacture bulk controlled

substances.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register
27592 Federal Register / Vol. 63, No. 96 /Tuesday, May 19, 1998 / Notices

Representative (CCR), and must be filed

no later than (30 days from publication).

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34 (a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: May 5, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13327 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on February 20,

1998, Stepan Company, Natural

Products Department, 100 W. Hunter

Avenue, Maywood, New Jersey 07607,

made application by renewal to the

Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basic classic classes

of controlled substances listed below:

Drug Schedule

Cocaine (9041) ............................. II

Benzoylecgonine (9180) ............... II

The firm plans to manufacture bulk

controlled substances for distribution to

its customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 20,

1998.

Dated: May 5, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13329 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Office of Justice Programs

Agency Information Collection

Activities: Proposed Collection;

Comment Request

ACTION: Notice of information collection

under review; (reinstatement, without

change, of a previously approved

collection for which approval has

expired).

Nomination for Young American Medal

for Bravery

The Department of Justice, Office of

Justice Programs, Bureau of Justice

Assistance, has submitted the following

information collection request for

review and clearance in accordance

with the Paperwork Reduction Act of

1995. This proposed information

collection is published to obtain

comments from the public and affected

agencies. Comments are encouraged and

will be accepted for ‘‘sixty days’’ until

July 20, 1998.

Written comments and suggestions

from the public and affected agencies

concerning the proposed collection of

information should address one or more

of the following four points:

(1) Evaluate whether the proposed

collection of information is necessary

for the proper performance of the

function of the agency, including

whether the information will have

practical utility;

(2) Evaluate the accuracy of the

agency’s estimate of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used;

(3) Enhance the quality, utility, and

clarity of the information to be

collected; and

(4) Minimize the burden of the

collection of information on those who

are to respond, including through the

use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology,

e.g., permitting electronic submission of

responses.

Overview of this information.

(1) Type of information:

Reinstatement, without change, of a

previously approved collection for

which approval has expired.

(2) The title of the form/collection:

Nomination for Young American Medal

for Bravery.

(3) The agency form number, if any,

and the applicable component of the

Department sponsoring the collection:

The form number is 1673/1, Office of

Justice Programs, United States

Department of Justice.

(4) Affected public who will be asked

or required to respond, as well as a brief

abstract: Primary: Federal Government,

State, Local or Tribal. Other: Individuals

or households; Not-for-profit

institutions. 42 U.S.C. 1921 et seq.

authorizes the Department of Justice to

collect information from state governors,

chief executives of the U.S. territories,

and the mayor of the District of

Columbia to implement the Young

American Medals Program.

(5) An estimate of the total number of

respondents and the amount of time

estimated for an average respondent to

respond/reply: It is estimated that 20

respondents will complete a 3-hour

nomination form.

(6) An estimate of the total public

burden (in hours) associated with the

collection: The total hour burden to

complete the nominations is 60 annual

burden hours.

If you have additional comments,

suggestions, or need a copy of the

proposed information collection

instrument with instructions or

additional information, please contact

Ellen Wesley, 202–616–3558, Office of

Budget and Management Services,

Office of Justice Programs, U.S.

Department of Justice, 810 7th Street,

N.W., Washington, DC 20531.

If additional information is required

contact: Mrs. Brenda E. Dyer, Deputy

Clearance Officer, United States

Department of Justice, Information

Management and Security Staff, Justice

Management Division, Suite 850,

Washington Center, 1001 G Street, N.W.,

Washington, DC 20530, or via facsimile

at (202) 514–1534.

Dated: May 12, 1998.

Brenda E. Dyer,

Department Deputy Clearance Officer, United

States Department of Justice.

[FR Doc. 98–13231 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–18–M